Leerink Partnrs Predicts Immunocore Q1 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Immunocore in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.48) per share for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s FY2025 earnings at ($1.78) EPS.

A number of other research analysts have also issued reports on IMCR. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, January 27th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a research note on Thursday. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Stock Performance

NASDAQ:IMCR opened at $29.58 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company’s 50-day moving average is $30.06 and its two-hundred day moving average is $31.95. Immunocore has a 1-year low of $27.69 and a 1-year high of $72.05. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -31.14 and a beta of 0.77.

Institutional Trading of Immunocore

Several hedge funds and other institutional investors have recently modified their holdings of IMCR. Geode Capital Management LLC raised its position in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock valued at $1,047,000 after purchasing an additional 420 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Immunocore in the 4th quarter valued at $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares in the last quarter. NEOS Investment Management LLC lifted its position in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Pier Capital LLC grew its stake in shares of Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock worth $2,568,000 after acquiring an additional 1,174 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.